Current Hepatitis Reports

, Volume 11, Issue 4, pp 256–262

Treatment of Chronic HCV in Special Populations: Thalassemia, Hemophilia, and Hemodialysis Patients

  • Seyed Moayed Alavian
  • Kamran Bagheri Lankarani
  • Ala I. Sharara
Global Perspectives: Middle East (SM Alavian and AI Sharara, Section Editors)

DOI: 10.1007/s11901-012-0147-1

Cite this article as:
Alavian, S.M., Lankarani, K.B. & Sharara, A.I. Curr Hepatitis Rep (2012) 11: 256. doi:10.1007/s11901-012-0147-1


Hepatitis C virus (HCV) infection is a common global health problem. Special patient populations such as those with thalassemia, hemophilia and on hemodialysis are at higher risk for acquiring this infection. Although the incidence of HCV infection has decreased in developed countries, it remains high in developing countries including the Middle East and North Africa region. Management of HCV infection in thalassemia is complicated by severe anemia limiting the use of ribavirin and coexisting iron overload while HCV management in hemophilia patients is more problematic often due to co-infection with HIV. Similarly, chronic kidney disease patients on hemodialysis have special treatment considerations in the management of HCV infection and current guidelines and treatment strategies are largely based on limited data. This review discusses the management the HCV infection in these special populations with emphasis on regional data and considerations.


Hepatitis CHemophiliaThalassemiaHemodialysisTherapyEpidemiologyMiddle East

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Seyed Moayed Alavian
    • 1
  • Kamran Bagheri Lankarani
    • 2
  • Ala I. Sharara
    • 3
  1. 1.Baqiyatallah Research Center for Gastroenterology and Liver DiseaseBaqiyatallah University of Medical SciencesTehranIran
  2. 2.Health Policy Research CenterShiraz University of Medical SciencesShirazIran
  3. 3.American University of Beirut Medical CenterBeirutLebanon